GILENYA® (fingolimod) Start Form and Prescrip Please complete all fields indicated to prevent any delays Attn: New York Prescribers	in filling the pre		des of all insurance plan cards.
1. Patient and Insurance Information			
Cannot process form without this completed			
		Insurance Name(s)	
First Name Last Name		modranico Namo(c)	
Sex: M F Other Date of Birth (MM/DD/YYYY)		Beneficiary/Cardholder Name(s)	
Sex: M F Other Date of Birth (MM/DD/YYYY)			
Home Phone Cell Phone		Insurance ID Number(s)	Group Number(s)
		Insurance Phone Number(s)	
E-mail Address (To make more communications convenient and paperless)		ea.aee :ee : taee,	
		Prescription Insurance Name	
Address (For patients in Puerto Rico, please provide physical address)			
		Prescription Insurance ID Number	Phone
City State ZIP		OK . I OH FADVA	
Name of Caraginar/Altarrate Cantast		OK to leave a GILENYA message on:	Cell Home Phone
Name of Caregiver/Alternate Contact		Primary Language: English S	Spanish Other
Cannot process form without this completed X Patient/Legal Guardian Signature I have read and agree to the attached Patient Authorization (page 2). Date of	Signature (MM/	DD/VVVVI	ext messages and calls as explained in the Telephone onsent on page 2. (optional) rtis Patient Assistance Foundation (NPAF) and Fair Credit ge 2. (optional)
FO!	R OFFICE U	JSE ONLY —	
2. Prescriber Information			
Cannot process form without this completed		Phone	Fax
First Name Last Name			
		State Medical License #	NPI #
Address / Site Name			
City State ZI	P	Office Contact Name	Office Contact Phone
		E-mail Address	
3. Assistance Requested From GILENYA Assessment Network (GAN)*			vill be completed even if assistance for treatment initiation is
GILENYA@Home [†] and/or GILENYA@Medical Facility [‡]		not requested. †Free to eligible commercially insured and uninsured patients. Health care professionals overseeing FDO via GAN	
Blood Tests: CBC LFTs and Bilirubin VZV Antibody Serolog		·	natients. Health care professionals overseeing FDO via GAN
	У	†Free to eligible commercially insured and uninsured p	batients. Health care professionals overseeing FDO via GAN nedications that may preclude the patients from completing
ECG Through the GAN	y ME Screening [§]	Free to eligible commercially insured and uninsured p will evaluate pre-existing conditions or concomitant of their FDO in a Novartis-sponsored facility. Medicare is accented at most GAN medical facilities.	nedications that may preclude the patients from completing There is a cash-nay option for residents of RL. This offer is
ECG Through the GAN	ME Screening§	**Free to eligible commercially insured and uninsured preview will evaluate pre-existing conditions or concomitant of their FDO in a Novartis-sponsored facility. **Medicare is accepted at most GAN medical facilities not valid for medical assessments for which payment programs, including but not limited to Medicare or M.	nedications that may preclude the patients from completing
	ME Screening§	Free to eligible commercially insured and uninsured p will evaluate pre-existing conditions or concomitant of their FDO in a Novartis-sponsored facility. *Medicare is accepted at most GAN medical facilities not valid for medical assessments for which payment	nedications that may preclude the patients from completing There is a cash-pay option for residents of RI. This offer is may be made in whole or in part under federal or state health edicaid, and for RI residents. This program is subject to
First-Dose Observation (FDO) Patient Is Cleared for FDO Scheduling Co-Pay Support Only	ME Screening§	There to eligible commercially insured and uninsured provide will evaluate pre-existing conditions or concomitant of their FDO in a Novartis-sponsored facility. Medicare is accepted at most GAN medical facilities not valid for medical assessments for which payment programs, including but not limited to Medicare or M termination or modification at any time. Macular Edema screening is available in select areas	nedications that may preclude the patients from completing There is a cash-pay option for residents of RI. This offer is may be made in whole or in part under federal or state health edicaid, and for RI residents. This program is subject to
First-Dose Observation (FDO) Patient Is Cleared for FDO Scheduling Co-Pay Support Only	ME Screening [§]	Three to eligible commercially insured and uninsured provide will evaluate pre-existing conditions or concomitant of their FDO in a Novartis-sponsored facility. Medicare is accepted at most GAN medical facilities not valid for medical assessments for which payment programs, including but not limited to Medicare or M termination or modification at any time. Macular Edema screening is available in select areas the shipping address:	nedications that may preclude the patients from completing There is a cash-pay option for residents of RI. This offer is may be made in whole or in part under federal or state health edicaid, and for RI residents. This program is subject to .
First-Dose Observation (FDO) Co-Pay Support Only 4. Starter Product Rx Starter product is optional and available at no cost to the patient. It is dispensed directly from the GILENYA Go Program®.	ME Screening [§] g Starter produc	Three to eligible commercially insured and uninsured partial evaluate pre-existing conditions or concomitant of their FDO in a Novartis-sponsored facility. Medicare is accepted at most GAN medical facilities not valid for medical assessments for which payment programs, including but not limited to Medicare or Materiniation or modification at any time. Macular Edema screening is available in select areas at shipping address: Address Prescriber's FDO Site on	nedications that may preclude the patients from completing There is a cash-pay option for residents of RI. This offer is may be made in whole or in part under federal or state health edicaid, and for RI residents. This program is subject to
First-Dose Observation (FDO) Patient Is Cleared for FDO Scheduling Co-Pay Support Only 4. Starter Product Rx Starter product is optional and available at no cost to the patient. It is dispensed directly from the GILENYA Go Program®. Dispense 2 boxes (7 capsules per box) of GILENYA 0.5 mg,	ME Screening [§] g Starter product Prescriber's GILENYA@	Three to eligible commercially insured and uninsured partial evaluate pre-existing conditions or concomitant of their FDO in a Novartis-sponsored facility. Medicare is accepted at most GAN medical facilities not valid for medical assessments for which payment programs, including but not limited to Medicare or M termination or modification at any time. Macular Edema screening is available in select areas at shipping address: Address Prescriber's FDO Site on Home or GILENYA@Medical Facility Others.	nedications that may preclude the patients from completing There is a cash-pay option for residents of RI. This offer is may be made in whole or in part under federal or state health edicaid, and for RI residents. This program is subject to File
First-Dose Observation (FDO) Co-Pay Support Only 4. Starter Product Rx Starter product is optional and available at no cost to the patient. It is dispensed directly from the GILENYA Go Program®.	ME Screening [§] g Starter produc	Three to eligible commercially insured and uninsured partial evaluate pre-existing conditions or concomitant of their FDO in a Novartis-sponsored facility. Medicare is accepted at most GAN medical facilities not valid for medical assessments for which payment programs, including but not limited to Medicare or M termination or modification at any time. Macular Edema screening is available in select areas at shipping address: Address Prescriber's FDO Site on Home or GILENYA@Medical Facility Others.	nedications that may preclude the patients from completing There is a cash-pay option for residents of RI. This offer is may be made in whole or in part under federal or state health edicaid, and for RI residents. This program is subject to File
First-Dose Observation (FDO) Patient Is Cleared for FDO Scheduling Co-Pay Support Only 4. Starter Product Rx Starter product is optional and available at no cost to the patient. It is dispensed directly from the GILENYA Go Program®. Dispense 2 boxes (7 capsules per box) of GILENYA 0.5 mg, 1 capsule taken by mouth once a day and, if needed,	ME Screening [§] g Starter product Prescriber's GILENYA@	Three to eligible commercially insured and uninsured partial evaluate pre-existing conditions or concomitant of their FDO in a Novartis-sponsored facility. Medicare is accepted at most GAN medical facilities not valid for medical assessments for which payment programs, including but not limited to Medicare or M termination or modification at any time. Macular Edema screening is available in select areas at shipping address: Address Prescriber's FDO Site on Home or GILENYA@Medical Facility Others.	nedications that may preclude the patients from completing There is a cash-pay option for residents of RI. This offer is may be made in whole or in part under federal or state health edicaid, and for RI residents. This program is subject to File ner Address (Provide Below)

I certify the above therapy is medically necessary and this information is accurate to the best of my knowledge. I certify I am the physician who has prescribed GILENYA to the previously identified patient. I have discussed the GILENYA Go Program with my patient, who has authorized me under HIPAA and state law to disclose their information to Novartis for the limited purpose of enrolling in the GILENYA Go Program. To complete this enrollment, Novartis may contact the project by phone tout and for a mail For the purpose of transmitting these propositions. Leathering NIPAE Novartis Phone positions and the first the purpose of transmitting these propositions and the project of the project of the previous phone tout and the project of the project of

Alternate instructions:

Additional notes:

limited purposes these prescriptions electronically, by facsimile, or by mail to the appropriate dispensing pharmacies. I will not attempt to seek reimbursement for free product provided to me for purposes of performing a first-dose observation. I have read and agree to the Prescriber Authorization for the NPAF on page 2.
Cannot process form without this completed

(Brand Exchange Permissible)

Date of Signature (MM/DD/YYYY)

page 1

Dispense (check one):

Primary diagnosis: ICD-10: G35 or Other:

Prescriber Signature (Dispense as Written)

1-month supply followed by 11 refills. Take $0.5\ \mathrm{mg}$ by mouth once a day. 3-month supply followed by 3 refills. Take 0.5 mg by mouth once a day.

Please read the following carefully, then sign and date where indicated on the previous page.

Patient Authorization. I give permission for my health care providers (HCPs), pharmacies, health insurer(s), third party contractors, and service providers to disclose my personal information, including information about my insurance, prescriptions, medical condition, and health ("Personal Information") to Novartis Pharmaceuticals Corporation, its affiliates, business partners, and agents (the "Novartis Group") and to the Novartis Patient Assistance Foundation, Inc. ("NPAF") so that the Novartis Group and NPAF can (i) help verify or coordinate insurance coverage or otherwise obtain payment for my treatment with GILENYA, (ii) coordinate my receipt of and payment for GILENYA, (iii) facilitate my access to GILENYA, (iv) provide me with information about GILENYA, disease awareness, management programs, and educational materials, (v) manage the GILENYA *Go Program*®, (vi) provide me with adherence reminders and support, (vii) conduct quality assurance, surveys, and other internal business activities in connection with the GILENYA *Go Program*, and (viii) if I choose to apply to programs offered by the NPAF, to administer those programs, to send me information about programs that might help me pay for my medicines, and to coordinate and share my Personal Information with my health care providers, other programs that might help me pay for medicines, government agencies, and insurance companies for purposes of providing or facilitating this assistance.

I give permission to the Novartis Group and NPAF to disclose my Personal Information to my health care providers, pharmacies, health insurer(s), caregivers, and other third-party contractors or service providers for the purposes described above. I also give permission to the Novartis Group and NPAF to combine or aggregate any information collected from me with information the Novartis Group and NPAF may collect about me from other sources for the purpose of providing or administering Program services.

I understand that my pharmacy, health insurer(s), and health care providers may receive remuneration (payment) from the Novartis Group in exchange for disclosing my Personal Information to the Novartis Group and/or for providing me with therapy support services.

I understand that once my Personal Information is disclosed it may no longer be protected by federal and state privacy law. I understand that I may refuse to sign this authorization. I also may revoke (withdraw) this authorization with respect to the GILENYA *Go Program* at any time in the future by calling 1-888-NOW-NOVA (1-888-669-6682) or by writing to the Customer Interaction Center, Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ 07936-1080. I also may revoke (withdraw) this authorization with respect to NPAF at any time in the future by calling 1-800-277-2254.

My refusal or future revocation will not affect the commencement or continuation of my treatment by my doctors; however, if I revoke this authorization, I may no longer be able to participate in the GILENYA *Go Program* and/or programs administered by NPAF. If I revoke this authorization, the Novartis Group and/or NPAF will stop using or sharing my information (except as necessary to end my participation in the program and/or NPAF) but my revocation will not affect uses and disclosures of Personal Information previously disclosed in reliance upon this authorization. I understand that this authorization will remain valid for five (5) years after the date of my signature, unless I revoke it earlier. I also understand that the GILENYA *Go Program* and/or programs administered by NPAF may change or end at any time without prior notification. I understand that I may receive a copy of this authorization.

I agree to be contacted by the Novartis Group and NPAF by mail, e-mail, telephone calls, and text messages at the number(s) and address(es) provided on the Start Form for all purposes described in this Patient Authorization. I also agree to be contacted by the Novartis Group, NPAF, and others on its behalf by telephone calls and text messages made by or using an automatic telephone dialing system or pre-recorded voice, at the number(s) provided on this form, for all non-marketing purposes, including but not limited to sending me materials and asking for my participation in surveys. I confirm that I am the subscriber for the telephone number(s) provided and the authorized user for the e-mail address(es) provided, and I agree to notify the Novartis Group and/or NPAF promptly if any of my numbers or addresses change in the future. I understand that my wireless service provider's message and data rates may apply.

I understand that the Novartis Group and NPAF do not permit my Personal Information to be used by its business partners for their own separate marketing purposes. I understand and agree that Personal Information transmitted by e-mail and cell phone cannot be secured against unauthorized access.

Telephone Consumer Protection Act (TCPA) Consent

I consent to receive marketing calls and texts from and on behalf of Novartis Pharmaceuticals Corporation, made with an auto dialer or prerecorded voice, at the phone number(s) provided. I understand that my consent is not required or a condition of purchase. I agree to the TCPA Terms & Conditions. Number of messages will vary based on your program selections. Message and data rates may apply. Text STOP to opt out and HELP for help. I understand that I can read the full Novartis Pharmaceuticals Corporation Privacy Policy at www.usprivacy.novartis.com.

Co-Pay Assistance Program Terms and Conditions Limitations apply. Up to an \$18,000 annual limit. Offer not valid under Medicare, Medicaid, or any other federal or state program. Novartis reserves the right to rescind, revoke, or amend this program without notice. Limitations may apply in MA and CA. See complete Terms & Conditions for details at GILENYA.com.

Novartis Patient Assistance Foundation, Inc. (NPAF) and Fair Credit Reporting Act (FCRA) Authorization I understand that I am providing "written instructions" authorizing NPAF and its vendor, under the FCRA, to obtain information from my credit profile or other information from Experian Health, solely for the purpose of determining financial qualifications for programs administered by NPAF. I understand that I must affirmatively agree to these terms in order to proceed in this financial screening process. I promise that any information, including financial and insurance information that I provide are complete and true and, unless I have indicated otherwise, I have no drug insurance coverage, which includes Medicaid, Medicare, or any public or private assistance programs or any other form of insurance. If my income or health coverage changes, I will call NPAF at 1-800-277-2254. If eligible, I would like to be considered for programs administered by NPAF.

Prescriber Authorization for the Novartis Patient Assistance Foundation, Inc. (NPAF) I certify that any medication received will be used only for the patient named on this form and will not be offered for sale, trade, or barter. Further, no claim for reimbursement will be submitted concerning this medication, nor will any medication be returned for credit. I acknowledge that NPAF is exclusively for purposes of patient care and not for remuneration of any sort. I understand that NPAF may revise, change, or terminate programs at any time.

GILENYA is a registered trademark of Novartis AG. GO PROGRAM is a registered trademark of Novartis AG. Please see the Novartis Pharmaceuticals Corporation Privacy Policy at www.novartis.us/privacy-policy.



page 2